Cargando…

Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib

The proteasomal system is responsible for the turnover of damaged proteins. Because of its important functions in oncogenesis, inhibiting the proteasomal system is a promising therapeutic approach for cancer treatment. Bortezomib (BTZ) is the first proteasome inhibitor approved by FDA for clinical a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karademir, Betul, Sari, Gulce, Jannuzzi, Ayse Tarbin, Musunuri, Sravani, Wicher, Grzegorz, Grune, Tilman, Mi, Jia, Hacioglu-Bay, Husniye, Forsberg-Nilsson, Karin, Bergquist, Jonas, Jung, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218500/ https://www.ncbi.nlm.nih.gov/pubmed/30397214 http://dx.doi.org/10.1038/s41598-018-34507-3

Ejemplares similares

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib
por: Jannuzzi, Ayse Tarbin, et al.
Publicado: (2020)

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events
por: Tsakiri, Eleni N., et al.
Publicado: (2017)

Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect
por: Malacrida, A., et al.
Publicado: (2021)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Exploring the Anticancer Effects of Brominated Plastoquinone Analogs with Promising Cytotoxic Activity in MCF-7 Breast Cancer Cells via Cell Cycle Arrest and Oxidative Stress Induction
por: Jannuzzi, Ayse Tarbin, et al.
Publicado: (2022)

An Overview of Bortezomib-Induced Neurotoxicity
por: Meregalli, Cristina
Publicado: (2015)

Scavenger Receptor A Mediates the Clearance and Immunological Screening of MDA-Modified Antigen by M2-Type Macrophages
por: Warnecke, Andreas, et al.
Publicado: (2017)

Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines
por: Takahashi, Kazuya, et al.
Publicado: (2017)

Proteomic differences between focal and diffuse traumatic brain injury in human brain tissue
por: Abu Hamdeh, Sami, et al.
Publicado: (2018)

Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
por: Lee, Min Seung, et al.
Publicado: (2021)

Distribution of Midbrain Cholinergic Axons in the Thalamus
por: Huerta-Ocampo, Icnelia, et al.
Publicado: (2020)

Omicron severity: milder but not mild
por: Nealon, Joshua, et al.
Publicado: (2022)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023)

Interactome analysis of Bag-1 isoforms reveals novel interaction partners in endoplasmic reticulum-associated degradation
por: Can, Nisan Denizce, et al.
Publicado: (2021)

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
por: Chng, W-J, et al.
Publicado: (2017)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)
por: Yong, Kwee L., et al.
Publicado: (2021)

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi
por: Csizmadia, Vilmos, et al.
Publicado: (2016)

Extrinsic Sources of Cholinergic Innervation of the Striatal Complex: A Whole-Brain Mapping Analysis
por: Dautan, Daniel, et al.
Publicado: (2016)

Omicron infection milder in nursing home residents
por: Katz, Morgan J, et al.
Publicado: (2022)

Therapierefraktäre Hypernatriämie bei milder COVID-19
por: Künzler, T., et al.
Publicado: (2021)

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
por: Moreau, P, et al.
Publicado: (2017)

Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis
por: Xie, Chunhong, et al.
Publicado: (2022)

Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion
por: Snavely, Andrew R., et al.
Publicado: (2022)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

In Vitro and In Silico Study to Assess Toxic Mechanisms of Hybrid Molecules of Quinone-Benzocaine as Plastoquinone Analogues in Breast Cancer Cells
por: Yilmaz Goler, Ayse Mine, et al.
Publicado: (2022)

Milder disease with Omicron: is it the virus or the pre-existing immunity?
por: Sigal, Alex
Publicado: (2022)

Milder COVID-19 in children with inborn errors of immunity
por: Yadav, Anjali, et al.
Publicado: (2022)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Promising Antibacterial and Antifungal Agents Based on Thiolated Vitamin K3 Analogs: Synthesis, Bioevaluation, Molecular Docking
por: Yıldırım, Hatice, et al.
Publicado: (2022)

Milder forms of muscular dystrophy associated with POMGNT2 mutations
por: Endo, Yukari, et al.
Publicado: (2015)

Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy
por: de Feraudy, Yvan, et al.
Publicado: (2020)

Why is the SARS-CoV-2 Omicron variant milder?
por: Xia, Bingqing, et al.
Publicado: (2022)

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

P857: BORTEZOMIB- AND CARFILZOMIB-RESISTANT MYELOMA CELLS SHOW INCREASED ACTIVITY OF ALL THREE ARMS OF UNFOLDED PROTEIN RESPONSE AND ENRICHMENT OF SIRTUIN SIGNALING PATHWAY
por: Kubicki, T., et al.
Publicado: (2022)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma
por: Maschio, Marta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_flbk3pdbq7p1v66snb7jjgci00